TBC

16:30 Welcome

R. Guymer AUSTRALIA

16:32 HONU: a multicenter, prospective, observational study of the progression of intermediate age-related macular degeneration

M. Pfau GERMANY

17:38 Impact of the Complement C3 Inhibitor Pegcetacoplan on Photoreceptor Degeneration beyond Areas of Geographic Atrophy

Y. Lechanteur THE NETHERLANDS

16:44 Early-Onset Drusen Maculopathy is associated with rare genetic variants in the complement factor H gene and an early onset of endstage disease.

D. Barthelmes SWITZERLAND

16:50 Artificial Intelligence-Quantified Macular Fluid Volumes Impact 12 and 48 Month Treatment Outcomes in Eyes with Neovascular Age-Related Macular Degeneration – Data from the Fight Retinal Blindness! Project Zurich

B. Gerendas AUSTRIA

16:56 Deep learning-based automated fluid monitoring from real-world management of neovascular AMD over five years

K. Teo SINGAPORE

17:02 Association between retinal thickness variation and visual acuity change in neovascular age-related macular degeneration

L. Gonzalez-Buendia USA

17:08 Topical RUNX1 inhibition for the treatment of ocular neovascularization

S. Rizzo ITALY

17:14 Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration: End-of-Study Results

M. Becker SWITERLAND

17:20 Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure

All Faculty

17:26 Discussion